Search results
Results from the WOW.Com Content Network
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
[1] [2] It is a combination of trastuzumab and hyaluronidase. [ 1 ] [ 2 ] [ 3 ] The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction , upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity.
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [31] [28] [32] [33] It is specifically used for cancer that is HER2 receptor positive. [31]
A decades-old cosmetic procedure called mesotherapy, which involves injecting unregulated mixtures of vitamins and drugs under the skin to reduce under-eye bags, is regaining popularity in the US.
Nivolumab/hyaluronidase, sold under the brand name Opdivo Qvantig, is a fixed-dose combination anti-cancer medication used for the treatment of various forms of cancer. [ 1 ] [ 2 ] Nivolumab/hyaluronidase contains nivolumab , a programmed death receptor-1 (PD-1)-blocking monoclonal antibody ; and hyaluronidase , an endoglycosidase . [ 1 ]
At just 19 years old, Eldiara Doucette — known on social media as "Bionic Barbie" — was diagnosed with synovial sarcoma, a rare form of soft tissue cancer that affects only 1,000 people per ...
Elevated tissue expression of hyaluronic acid and hyaluronidase validates the hyaluronic acid-hyaluronidases urine test for bladder cancer. [48] Limited data support a role of lysosomal hyaluronidases in metastasis, while other data support a role in tumor suppression. Other studies suggest no contribution or effects independent of enzyme activity.